Nidlegy

Nidlegy is an investigational immunotherapeutic combination consisting of two immunocytokines: L19IL2 (darleukin) and L19TNF (fibromun). Developed by Philogen S.p.A., it is designed for intratumoral administration. Each component consists of a specific cytokine (Interleukin-2 or Tumor Necrosis Factor) fused to the L19 antibody fragment, which targets the Extra-Domain B (ED-B) of fibronectin. ED-B fibronectin is a marker of neo-angiogenesis that is highly expressed in the stroma of many solid tumors but virtually absent in most healthy tissues. By delivering IL2 and TNF directly to the tumor microenvironment, Nidlegy aims to induce a potent local inflammatory response and activate a systemic anti-tumor immune response while minimizing the systemic toxicities typically associated with these cytokines. It is currently in Phase III clinical trials as a neoadjuvant treatment for patients with resectable Stage III B/C melanoma.

Brand names

Nidlegy

Other names

Daromundarleukin + fibromun